Search results
Results from the WOW.Com Content Network
A BiTE linking a T cell to a tumor cell. Like other bispecific antibodies, and unlike ordinary monoclonal antibodies, BiTEs form a link between T cells and tumor cells. This causes T cells to exert cytotoxic activity on tumor cells by producing proteins like perforin and granzymes, independently of the presence of MHC I or co-stimulatory molecules.
The first bispecific antibody to gain regulatory approval, blinatumomab, targets CD19 on B cells and CD3 on T cells, leading to the activation of T cells and the destruction of B cells. [31] Additional bispecific antibody drugs have since been approved by the US FDA: emicizumab, amivantamab, tebentafusp, faricimab, teclistamab, mosunetuzumab ...
Epcoritamab, sold under the brand name Epkinly, is a monoclonal antibody anticancer medication used for the treatment of diffuse large B-cell lymphoma. [4] [7] Epcoritamab is a bispecific CD20-directed CD3 T-cell engager. [4] [7] Epcoritamab was co-developed by AbbVie and Genmab. [8]
The first and only therapy for unresectable or metastatic uveal melanoma to be approved by the FDA. Related: Immunocore Tebentafusp Show ... First bispecific T cell engager to receive FDA approval ...
Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer. [4] It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3.
Blinatumomab linking a T cell to a malignant B cell. Blinatumomab is a bispecific T-cell engager (BiTE). [7] It enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells. CD3 is part of the T cell receptor.
A trifunctional antibody is a monoclonal antibody with binding sites for two different antigens, typically CD3 and a tumor antigen, making it a type of bispecific monoclonal antibody. In addition, its intact Fc-part can bind to an Fc receptor on accessory cells like conventional monospecific antibodies.
Hospitals across the country reported mothers to authorities after they tested positive for medications used routinely in millions of births.